We investigated all patients for fusions with FGFR, neurotrophin tyrosine receptor kinase (NTRK), and MET and identified NTRK2 in one patient with a MGMT‐methylated tumor and FGFR3‐TACC3 in 3 patients (2.8%) all of which were in MGMT‐unmethylated tumors. This evidence concerns the gene NTRK2 and neoplasm.